Abstract Details

Title Harnessing AI-Driven Mobile Applications for Cognitive Impairment Screening

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-002

Objective This study evaluates the efficacy of the BeCareLink mobile app in detecting cognitive impairment through quantification of neurologic function.

Background The diagnosis of Alzheimer’s disease often relies on a “rule out” approach, yielding only a 60% accuracy rate. With advancements in diagnostic tools for early cognitive impairment, there is a critical need for an accessible screening method to detect pre-clinical changes and improve patient outcomes. Digital technologies combined with artificial intelligence (AI) offer a novel strategy for early detection.

Design/Methods The BeCare Neuro App collects user-reported symptoms and measures aspects of neurologic function via gamified activities. It assesses cognitive skills across four domains using tasks similar to those in comprehensive neuropsychological exams, reporting performance against normative scores. Key tasks include: the “Cognitive Test” (decoding messages by pairing symbols with letters), the “Stroop Test” (naming the color of displayed words), the “Memory Test” (recalling a disappearing animal), and the “Tap Test” (tapping randomly appearing coins). The app has over 13,000 users and has recorded significant completions across all tests. It computes population percentiles based on combined time and accuracy metrics.

Results Sixty-five users who completed all tests and reported “cognitive” or “memory loss” were analyzed. Users consistently scored in the bottom third of the population. Specifically, 90.8% (59/65) had at least one activity in the bottom third, 66.2%(43/65) had two or more, and 30.8% had three or more activities in that range.

Conclusions The BeCare Neuro App demonstrates potential as a screening tool for pre-clinical and early cognitive impairment, assisting clinicians in identifying patients who may require further evaluation.

Authors/Disclosures
Charisse D. Litchman, MD PRESENTER	Dr. Litchman has received personal compensation for serving as an employee of BeCare . Dr. Litchman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nurx. Dr. Litchman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan.
larry rubin	No disclosure on file
Sharon Stoll, DO (Stoll Medical Group)	Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for roche Genentech. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi/genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Stoll has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for alexion. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Stoll has stock in BeCare Link LLC. Dr. Stoll has stock in Global Consult MS .

��ɫ��

��ɫ��